Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 18, 2010, Pages 5559-5566

  Lucas, Matthew C ^a   Weikert, Robert J ^a   Carter, David S ^a   Cai, Hai Ying ^a   Greenhouse, Robert ^a   Iyer, Pravin S ^a   Lin, Clara J ^a   Lee, Eun Kyung ^a   Madera, Ann Marie ^a   Moore, Amy ^a   Ozboya, Kerem ^a   Schoenfeld, Ryan C ^a   Steiner, Sandra ^a   Zhai, Yansheng ^a   Lynch, Stephen M ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Depression; Dopamine; Major depressive disorder; Monoamine reuptake inhibitors; Noradrenalin; Norepinephrine; Serotonin; Triple reuptake inhibitor

Indexed keywords

2 PYRROLIDONE DERIVATIVE; DOPAMINE TRANSPORTER; DULOXETINE; POTASSIUM CHANNEL HERG; SEROTONIN TRANSPORTER; TRIPLE REUPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CELL STRAIN CACO 2; DEPRESSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CACO-2 CELLS; DEPRESSION; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DRUG DESIGN; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PAIN; PYRROLIDINES; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 77956179033     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.020     Document Type: Article

References (31)

1. R.J. Baldessarini J.G. Hardman, L.E. Limbird, A.G. Gilman, The Pharmacological Basis of Therapeutics 10th ed. 2001 McGraw-Hill 451 483
2. C.B. Nemeroff J. Psychiatry Res. 41 2007 189
3. M.W. Walter Drug Dev. Res. 65 2005 97
4. S. Liu, and B.F. Molino Annu. Rep. Med. Chem. 42 2007 13
5. E.K. Moltzen, and B. Bang-Andersen Curr. Top. Med. Chem. 6 2006 1801
6. J.M. Zajecka, and D. Albano J. Clin. Psychiatry 65 2004 11
7. C.B. Nemeroff, R. Entsuah, I. Benattiab, M. Demitrack, D.M. Sloan, and M.E. Thase Biol. Psychiatry 63 2008 424
8. L.H. Pedersen, A.N. Nielsen, and G. Blackburn-Munro Psychopharmacology 182 2005 551
9. B.P. Guiard, M. El Mansari, and P. Blier Curr. Drug Targets 10 2009 1069
10. D.M. Marks, C.-U. Pae, and A.A. Patkar Curr. Neuropharmacol. 6 2008 338
11. P. Skolnick, and Z. Chen Expert. Opin. Invest. Drugs 16 2007 1365
12. M.R. Lemke, H.M. Brecht, J. Koester, and H. Reichmann J. Neuro. Sci. 248 2006 266
13. M.H. Trivedi, M. Fava, S.R. Wisniewski, M.E. Thase, F. Quitkin, D. Warden, L. Ritz, A.A. Nierenberg, B.D. Lebowitz, M.M. Biggs, J.F. Luther, K. Shores-Wilson, and A.J. Rush N. Eng. J. Med. 354 2006 1243
14. L.M. Bannwart, D.S. Carter, H.-Y. Cai, J.C. Choy, R. Greenhouse, S. Jaime-Figueroa, P.S. Iyer, C.J. Lin, E.K. Lee, M.C. Lucas, S.M. Lynch, A.M. Madera, A. Moore, K. Ozboya, L. Raptova, R. Roetz, R.C. Schoenfeld, K.A. Stein, S. Steiner, M. Villa, R.J. Weikert, and Y. Zhai Bioorg. Med. Chem. Lett. 18 2008 6062
15. Greenhouse, R.; Jaime-Figueroa, S.; Raptova, L.; Reuter, D. C.; Stein, K. A.; Weikert, R. J. WO2005118539A1, 2005.
16. Iyer, P.; Lucas, M. C.; Schoenfeld, R. C.; Villa, M.; Weikert, R. J. US20070123527(A1), 2007.
17. Greenhouse, R.; Jamie-Figueroa, S.; Lynch, S. M.; Raptova, L.; Stein, K. A.; Weikert, R. J. US2007123535(A1), 2007.
18. M.P. Gleeson J. Med. Chem. 51 2008 817
19. M.J. Waring, and C. Johnstone Bioorg. Med. Chem. Lett. 17 2007 1759
20. int measured in HT format: total incubation volume 250 μL, 0.5 mg/mL microsomal protein, reaction started by adding NADPH and performed at 37 °C with no shaking. 40 μL aliquots at four time-points (0.1, 10, 20 and 30 min) were taken then the samples transferred to 384 well plates for LC/MS analysis.
21. + currents in CHO cells expressing the human ERG channel. Recordings were made at 30 °C with test compounds at two concentrations (1 μM, 10 μM) or more.
22. app A to B and B to A) values. Substrate concentration 10 μM.
23. D. Seebach, A.R. Sting, and M. Hoffmann Angew. Chem., Int. Ed. 35 1996 2708
24. L. Steru, R. Chermat, B. Thierry, and P. Simon Psychopharmacology 85 1985 67
25. CYP2D6 inhibition was measured in a fluorescence based assay where CYP marker substrates become fluorescent upon CYP metabolism.
26. P.E. Mahaney, C.Y. Kim, R.D. Coghlan, S.T. Cohn, G.D. Heffernan, C.A. Huselton, E.A. Terefenko, A.T. Vu, P. Zhang, K.D. Burroughs, S.A. Cosmi, J.A. Bray, G.H. Johnston, D.C. Deecher, and E.J. Trybulski Bioorg. Med. Chem. Lett. 19 2009 5807
27. C.Y. Kim, P.E. Mahaney, O. McConnell, Y. Zhang, E. Manas, D.M. Ho, D.C. Deecher, and E.J. Trybulski Bioorg. Med. Chem. Lett. 19 2009 5029
28. A.S. Kalgutkar A.A. Elfarra, Biotechnology: Pharmaceutical Aspects (Advances in Bioactivation Research) Vol. 9 2008 Springer 27 55
29. J.-F. Levesque, S.H. Day, N. Chauret, C. Seto, L. Trimble, K.P. Bateman, J.M. Silva, C. Berthelette, N. Lachance, M. Boyd, L. Li, C.F. Sturino, Z. Wang, R. Zamboni, R.N. Young, and D.A. Nicoll-Griffith Bioorg. Med. Chem. Lett. 17 2007 3038
30. A.M. Aronov Curr. Top. Med. Chem. 8 2008 1113
31. X. Liu, O. Vilenski, J. Kwan, S. Apparsundaram, and R. Weikert Drug Metab. Dispos. 37 2009 1548